Evidence map›Paper›PMID 42595803›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Ziyi Yang, Zhihuang Hu, Xiaoping Xu, Qiufang Liu, Zhenhua Wu, Huijie Wang, Jianping Zhang, Jindian Li, Jialei Wang, Shaoli Song

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ziyi Yang *Department of Nuclear Medicine, Shanghai Cancer Center, Fudan University, Shanghai, China.
Zhihuang Hu *Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Xiaoping XuDepartment of Nuclear Medicine, Shanghai Cancer Center, Fudan University, Shanghai, China.
Qiufang LiuDepartment of Nuclear Medicine, Shanghai Cancer Center, Fudan University, Shanghai, China.
Zhenhua WuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Huijie WangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Jianping ZhangDepartment of Nuclear Medicine, Shanghai Cancer Center, Fudan University, Shanghai, China.
Jindian LiDepartment of Nuclear Medicine, Shanghai Cancer Center, Fudan University, Shanghai, China.
Jialei WangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. wangjialei@shca.org.cn.
Shaoli SongDepartment of Nuclear Medicine, Shanghai Cancer Center, Fudan University, Shanghai, China. shaoli-song@163.com.ORCID http://orcid.org/0000-0003-2544-7522

Funding

National Natural Science Foundation of China 12275057National Natural Science Foundation of China 82272035National Natural Science Foundation of China U23A20465
6 · The paper itself

Abstract

purposeThis study aimed to evaluate

methodsIn this prospective single-center trial (ChiCTR2200062089), 41 stage IIIB/IV non-small lung cancer patients underwent

resultsResponders (n = 29) showed significantly higher SUV

conclusion⁶⁸Ga-NOTA-GSI PET/CT parameters, particularly SUV

Indexed as

⁶⁸Ga-NOTA-GSI PET/CTImmune responseNomogramNon‑small cell lung cancerProgression‑free survival

Identifiers

PMID42595803

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.